Immunic Appoints Erik Lundgren as CEO
Immunic announced the appointment of Erik Lundgren as CEO, effective May 22, with employment beginning on June 1. Lundgren succeeds Daniel Vitt, who will retain responsibility for scientific strategy and portfolio advancement while remaining a member of Immunic's board of directors. Lundgren will lead Immunic as the company advances vidofludimus calcium through late-stage clinical development, including the phase 3 ENSURE program in relapsing multiple sclerosis and the planned phase 3 program in primary progressive multiple sclerosis, while also preparing for potential new drug application filing, regulatory approval and commercialization. Lundgren spent more than a decade at Genentech in roles of increasing responsibility.
